FDA Grants Fast Track Designation to PTC518 Huntington's …
WEB16 hours ago — WARREN, N.J., Sept. 26, 2024 /PRNewswire/ -- PTC Therapeutics (NASDAQ: PTCT) announced today that the FDA has granted Fast Track designation to the PTC518 program for the treatment of Huntington's ...
Interim PIVOT-HD Results Demonstrate Evidence of Favorable CNS ...
WEBJun 20, 2024 — At Month 12, PTC518 treatment resulted in dose-dependent lowering of mutant huntingtin (mHTT) protein in the blood and cerebrospinal fluid (CSF) in the interim cohort of patients. In addition, favorable trends were demonstrated on several relevant HD clinical assessments including Total Motor Score …
Huntington Agent PTC518 Demonstrates Significant Reduction in …
WEBJun 21, 2023 — Newly announced interim data from the phase 2 PIVOT study (NCT05358717) of PTC518 (PTC Therapeutics), an agent in development for Huntington disease (HD), showed a dose-dependent lowering of huntingtin protein (HTT) levels after 12 weeks of treatment.
PTC today announced promising 12 month results from their …
WEBJun 20, 2024 — In addition PTC518 treatment resulted in a notable slowing in progression of motor symptoms at month 12, as assessed by the Total Motor Score (2.0 points worsening for 5mg and 1.3 points worsening for 10mg vs. 4.9 points worsening for placebo).
PTC Provides Update on Ongoing Global PIVOT-HD Trial For PTC518
WEBOct 18, 2022 — SOUTH PLAINFIELD, N.J., Oct. 18, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) confirmed today that enrollment is active and ongoing for its Phase 2 PIVOT-HD trial of PTC518 for the...
PTC Therapeutics Shares Positive Interim Data from PIVOT-HD …
WEBJun 21, 2023 — PTC518, a small molecule that can be taken orally, reduces the production of the mutated Huntingtin protein that leads to injury and death of the neuron, which results in disease progression.
PTC Therapeutics' Huntington's Treatment Gets FDA Fast Track ...
WEB1 day ago — PTC518 was discovered through the development of another drug, Risdiplam, which treats spinal muscular atrophy. ... Dow Jones Newswires is a market-moving financial and business news source, used ...
Huntington's therapy PTC518 lowers mutant HTT, slows disease...
WEBJun 25, 2024 — An investigational oral therapy from PTC Therapeutics called PTC518 safely and effectively reduces levels of the mutant huntingtin protein (mHTT) in Huntington’s disease patients, while being linked to trends of slower disease progression.
FDA Grants Fast Track Designation to PTC518 Huntington's …
WEB1 day ago — WARREN, N.J., Sept. 26, 2024 /PRNewswire/ -- PTC Therapeutics (NASDAQ: PTCT) announced today that the FDA has granted Fast Track designation to the PTC518 program for the treatment of Huntington's disease. Fast Track designation is awarded to promising therapies for diseases of high unmet need. "The granting of Fast Track designation to the ...
FDA Grants Fast Track Designation to PTC518 Huntington's …
WEB1 day ago — PTC518 was discovered using PTC's innovative splicing platform, following the successful discovery and development of Evrysdi® (risdiplam) for the treatment of spinal muscular atrophy. In June 2024, PTC announced positive results from the 12-month interim data readout of the PIVOT-HD study of PTC518 Huntington's disease patients.